Stockholm - Free Realtime Quote SEK
Klaria Pharma Holding AB (publ.) (KLAR.ST)
1.1400
-0.0150
(-1.30%)
As of 12:07:48 PM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Scott Boyer | CEO & Director | 1.59M | -- | 1962 |
| Mr. Hans Richter | Chief Financial Officer on Consultative | -- | -- | 1949 |
| Mr. Marc Willuhn Ph.D. | Head of Chemistry, Manufacturing & Control | -- | -- | 1969 |
| Dr. Hans Olivecrona M.D., Ph.D. | Chief Medical Officer | -- | -- | 1958 |
Klaria Pharma Holding AB (publ.)
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 4
Description
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden.
Corporate Governance
Klaria Pharma Holding AB (publ.)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available